Arcadia Biosciences price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Arcadia Biosciences to $10 from $15 and keeps a Buy rating on the shares post the Q2 report. The company continues to explore a range of potential transactions and alternative strategies focused on maximizing long-term shareholder value, the analyst tells investors in a research note.